The Conversation (0)
M Pharmaceutical Inc. (CSE:MQ) detailed its 2015 plans for advancing the eMosquito, starting with the development of a pilot prototype of the eMosquito in Q2 of 2015, and pilot prototype testing of expecimental animals in Q4 of 2015. M Pharmaceutical also announced the closing of the final trench of its recents financing.
The Company also announced that it has closed the final tranche of its recently announced financing. The Company has issued an additional 10,250,000 units at $0.02 per unit for gross proceeds of $205,000, for final total gross proceeds of $1,080,000.
The Company also announced that it has closed the final tranche of its recently announced financing. The Company has issued an additional 10,250,000 units at $0.02 per unit for gross proceeds of $205,000, for final total gross proceeds of $1,080,000.
As quoted in the press release:
The following are the Company’s current milestone goals, together with an approximate timeline of achieving the same.
- Development of a pilot prototype of the eMosquito (Q2 2015)
- Preparation of a medical device registration strategy (Q2-Q3 2015)
- Pilot prototype testing in laboratory (Q3 2015)
- PCT Conversion/Continuous patent management (Q4 2015)
- Pilot prototype testing on experimental animals (Q4 2015)
Click here to read the M Pharmaceutical Inc. (CSE:MQ) press release